We and others have previously showed that in HCC cells and mouse preclinical models, Decitabine reduces tumorigenicity by decreasing levels of oncogenic signals,24,30,31 including the oncogene ADAMTSL5.29 Here, ADAMTSL5 is linked to hepatocellular carcinoma.